Market closed

Apellis Pharmaceuticals/$APLS

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Ticker

$APLS

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Waltham, United States

Employees

704

Website

www.apellis.com

APLS Metrics

BasicAdvanced

$3.6B

-

-$2.03

0.94 -

Price and volume

Market cap

$3.6B

Beta

0.94

52-week high

$71.90

52-week low

$24.34

Average daily volume

2.6M

Financial strength

Current ratio

4.36

Quick ratio

3.595

Long term debt to equity

195.536

Total debt to equity

198.4

Interest coverage (TTM)

-6.16%

Management effectiveness

Return on assets (TTM)

-16.23%

Return on equity (TTM)

-106.56%

Valuation

Price to revenue (TTM)

4.92

Price to book

14.72

Price to tangible book (TTM)

14.72

Price to free cash flow (TTM)

-17.117

Growth

Revenue change (TTM)

162.10%

Earnings per share change (TTM)

-61.10%

3-year revenue growth (CAGR)

40.79%

3-year earnings per share growth (CAGR)

-32.04%

What the Analysts think about APLS

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Apellis Pharmaceuticals stock.

APLS Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

APLS Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

APLS News

AllArticlesVideos

Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Connect

Accesswire·15 hours ago

Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Stockholders to Inquire about Securities Investigation

Accesswire·2 days ago

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewsWire·2 days ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $APLS

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Apellis Pharmaceuticals stock?

Apellis Pharmaceuticals (APLS) has a market cap of $3.6B as of January 15, 2025.

What is the P/E ratio for Apellis Pharmaceuticals stock?

The price to earnings (P/E) ratio for Apellis Pharmaceuticals (APLS) stock is 0 as of January 15, 2025.

Does Apellis Pharmaceuticals stock pay dividends?

No, Apellis Pharmaceuticals (APLS) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Apellis Pharmaceuticals dividend payment date?

Apellis Pharmaceuticals (APLS) stock does not pay dividends to its shareholders.

What is the beta indicator for Apellis Pharmaceuticals?

Apellis Pharmaceuticals (APLS) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.